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BACKGROUND: Oestrogens play a crucial role in breast carcinogenesis. Earlier studies have analysed the serum levels of endogenous
hormones measured by conventional assays. In this study, we analysed the capacity of serum from breast cancer cases and controls to
transactivate the oestrogen receptor a (ER-a) and b (ER-b).
METHODS: We used a receptor oestrogen-responsive element (ERE) – the green fluorescent protein (GFP)-reporter test system in
Saccharomyces cerevisiae. Oestrogen receptor-a or ER-b bioactivity was determined in serum from 182 randomly chosen
postmenopausal women with breast cancer and from 188 age-matched controls.
RESULTS: High serum ER-a and ER-b bioactivity were independently associated with the presence of breast cancer. Women whose
levels of serum ER-a and ER-b bioactivity were in the highest quintile among controls had a 7.57-(95% confidence interval (CI): 2.46–
23.32; P¼0.0004) and a 10.14 (95% CI: 3.19–32.23; Po0.0001)-fold risk for general and oestrogen receptor-positive breast cancer,
respectively.
CONCLUSION: The use of serum ER-a and ER-b bioactivity assays as clinical tools in the management of breast cancer warrants further
research. Future studies will dictate whether surrogate markers of ER-a and ER-b bioactivity will provide a means to monitor the
efficacy of anti-endocrine, adjuvant and chemopreventive strategies.
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Oestrogens are known to play a crucial role in breast carcinogen-
esis. High serum oestrogen levels (Toniolo et al, 1995; Thomas
et al, 1997; Hankinson et al, 1998; Cauley et al, 1999; Key et al,
2002; Missmer et al, 2004) and surrogates for long-term high
oestrogen exposure, such as bone (Zhang et al, 1997) density, are
known to be associated with an increased risk for breast cancer.
However, exposure to anti-oestrogens has been shown to decrease
the risk for breast cancer and recurrent disease (Baum et al, 2002;
Cuzick et al, 2003). A retrospective analysis of worldwide data in
postmenopausal women showed that elevated levels of endogenous
oestrogens further from the time of diagnosis seem to indicate a
greater risk for breast cancer than equivalent levels immediately
before diagnosis (Key et al, 2002).
Standard assays of steroid hormones, including oestrogens, are
based on various immunological detection methods. Although these
assays are widely used in routine clinical diagnosis and research, a
major limitation is that they do not reflect the level of hormonal
bioactivity in the sample, but rather the combined immunoreactivity
of compounds structurally related to the immunogen.
Oestrogens exert their action by binding to intracellular
oestrogen receptor (ER) proteins that, on dimerisation, bind to
specific DNA sequences (oestrogen-responsive elements (EREs))
in the regulatory regions of target gene promoters. The degree of
transcriptional stimulation in a particular cell type depends on the
pattern and concentration of the activated ER proteins and several
complex regulating factors. In addition to oestrogen metabolites,
environmental contaminants such as polycyclic aromatic hydro-
carbons, phthalates, pesticides and certain plant constituents,
termed phytoestrogens, bind and activate ER proteins (Cvoro et al,
2007; Heldring et al, 2007). Both oestrogen receptor a (ER-a) and b
(ER-b) have been shown to play independent and fundamental
roles in breast carcinogenesis (Yager and Davidson, 2006).
All earlier studies have only explored levels of endogenous
hormones with regard to breast cancer risk. Over the last decade,
several groups have developed bioactivity assays for steroid
hormones mainly to detect very-low hormone levels in children
(Klein et al, 1994, 1998; Paris et al, 2002; Roy et al, 2006). Recently,
we have described a receptor ERE-green fluorescent protein (GFP)-
reporter test system in Saccharomyces cerevisiae, which measures
activation of ER-a and ER-b independently. This transactivation
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sassay involves ER-a or ER-b receptors coupled to the ERE-GFP-
reporter in a genetically modified yeast strain, devoid of three
endogenous xenobiotic transporters (PDR5, SNQ2 and YOR1)
(Figure 1) (Sievernich et al, 2004; Hasenbrink et al, 2006).
In this paper, we analyse for the first time, oestrogen bioactivity
in serum from breast cancer cases and controls in addition to
endogenous hormone levels measured by a conventional immu-
noassay.
MATERIALS AND METHODS
Patients
All serum samples were collected as part of the population-based
study ESTHER, carried out in the state of Saarland, Germany. In
the hospital arm of this study, 1981 cancer patients aged 50–75,
including 380 women with breast cancer, were recruited after
diagnosis and at the first hospitalisation for initial cancer
treatment. In the community arm, 9953 women and men aged
50–75 were recruited during routine health examinations by their
general practitioners. Recruitment and baseline examinations were
carried out between 2000–2003. In both study arms, detailed
information of medical history, including family history, socio-
demographics, lifestyle factors and current health status, was
obtained using a standardised questionnaire. In addition, serum
and whole blood samples were collected. Serum samples were sent,
after centrifugation, to the study centre by regular mail, where they
were aliquoted and frozen at  801C until analysis. Procedures for
the collection, processing and storing of blood samples were
identical for both cases and controls. The written informed
consent was obtained from all subjects for use of the data and
samples in future ethically approved research. The protocol was
approved by the Ethics Committee of the Medical Faculty of the
University of Heidelberg, Germany. For the current study, we
analysed serum samples from 182 randomly chosen postmeno-
pausal women with breast cancer (mean age 62.1 years) and from
188 age-matched controls (mean age 62.5 years).
Serum oestradiol assay
Serum oestradiol was analysed on the Roche E170 analyser (Roche
Diagnostics GmbH, Mannheim, Germany) using a competitive
chemiluminescence immunoassay after release from binding
proteins by mesterolone. The assay uses 35ml of sample and has
a quoted detection limit of 5pgml
 1 with a functional sensitivity
(inter-assay coefficient of variation (CV)o20%) of 12pgml
 1,
intra-assay CV of 3.3% at 35.5pgml
 1 and inter-assay CV of 6.2%
at 22.9pgml
 1. The samples were analysed blind in batches over 4
days using a single lot number of reagent and calibrator.
ER-a and ER-b serum bioactivity assay
Serum oestradiol bioactivity was assessed using the transactivation
assay consisting of genetically modified yeast expressing the
human ER-a or ER-b receptor, as described earlier (Sievernich
et al, 2004; Hasenbrink et al, 2006). The analysis was performed
blinded, and cases and controls were randomly mixed and blinded
to the group at the University of Bonn, where the assays have been
performed. In brief, for quantitative assessment of growth
phenotypes and fluorescence development, logarithmic growing
cells were exposed to 20ml of serum aliquots. Tests were
carried out with two replicates at a time on two different days
(thus four readings in total) in transparent 96-well microtitre
plates using a microplate reader. Each experiment comprised of
0–10000pgml
 1 oestradiol concentration ranges (in 20% char-
coal-stripped serum) as reference values and positive controls.
Tests were considered as valid when the turbidity of the control
cultures increased at least five-fold during the incubation period of
16.5h. End-point fluorescence values were corrected for blanks
and normalised for cell number. Serum ER-a and ER-b bioactivity
were calculated from the oestradiol reference curve and expressed
as equivalent oestrogen activity accordant to oestradiol in
pgml
 1. Dose-response curves of the oestradiol reference values
were fitted as described earlier using the Hill equation fit and the
R function nls (The R Foundation for Statistical Computing,
http://www.r-project.org/) (Sievernich et al, 2004; Hasenbrink
et al, 2006). No temporal effects could be detected. By the nature
of the assay, minor daily performance differences may occur, but
were accounted for by including a daily reference curve,
comprising 10 different estradiol concentrations. Order effects
were not detected since, as mentioned above, all samples were
randomised before numerical coding.
Statistics
Breast cancer cases were described with respect to major tumour
characteristics and ER status (ER-positive and ER-negative) by
immunohistochemistry of the original tumour. Cases and controls
were described with respect to established breast cancer risk
factors. Mean and median levels of oestradiol, serum ER-a and
ER-b bioactivity were calculated for ER-positive, ER-negative, all
breast cancer samples and for controls. Differences in the means
between groups were tested for statistical significance using the
Kruskal–Wallis test. Correlations between oestradiol, serum ER-a
and ER-b bioactivity among cases and controls were assessed by
the Spearman’s rank correlation coefficient. The associations
between oestradiol, serum ER-a and ER-b bioactivity levels, and
the risk of ER-positive, ER-negative and total breast cancer risk,
were determined after controlling for age by multiple logistic
regression. Subjects were classified according to quintiles of the
respective marker among controls. Finally, serum ER-a and ER-b
bioactivity levels were jointly entered and controlled for in the
regression models to estimate their independent and combined
associations with breast cancer risk.
RESULTS
A total of 14 women with breast cancer and 63 controls were
excluded as they were using hormone replacement therapy at the
time of blood collection. The epidemiological risk factor profile for
the remaining 168 cases and 125 controls is shown in Supplemen-
tary Table 1. Cases were significantly more likely to have first-
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Figure 1 Principle of the oestrogen receptor bioactivity assay enabling
investigation of receptor-mediated transcriptional activation of the green
fluorescent protein optimised for expression in yeast (yEGFP3) under the
control of oestrogen-responsive elements (EREs). X: oestrogen receptor-a
(ER-a) or oestrogen receptor-b (ER-b), respectively; ERE 3 : three-fold
repeat of 50-GGGTCACAGTGACCGCTAG-30.
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sdegree relatives with breast cancer (odds ratio (OR) 3.16; 95%
confidence interval (CI): 1.09–9.21). Tumour characteristics of
the cases were similar to a typical breast cancer cohort
(Supplementary Table 2).
No difference was observed in serum oestradiol levels between
cases and controls (Supplementary Table 3). Serum ER-b
bioactivity was only detectable in 36 and 48.8% of controls and
cases, respectively. However, both serum ER-a and ER-b
bioactivity showed significant differences between all cases and
controls (Table 1). A difference for both ER-a and ER-b serum
bioactivity was shown between ER-positive breast cancer cases and
controls. In addition, there was also a clear trend, although not
significant, towards higher serum ER-b bioactivity in ER-negative
breast cancer cases compared with controls (Table 1).
Using all samples, no significant correlations among oestradiol,
ER-a and ER-b serum bioactivity were observed. Using only
samples with oestradiol above the lower threshold of the test
(412pgml
 1) showed a positive correlation between serum ER-a
bioactivity and oestradiol (Table 2). A borderline association
between ER-a and ER-b serum bioactivity was only observed after
samples with undetectable ER-b serum bioactivity have been
excluded.
The values for oestradiol, ER-a and ER-b serum bioactivity were
classified according to quintiles among controls. No association
with serum oestradiol could be observed (data not shown), but
both ER-a and ER-b serum bioactivity were significantly increased
in breast cancer samples. Women with X42.1pgml
 1 serum ER-a
bioactivity and 453pgml
 1 ER-b serum bioactivity had a 2.47-
(95% CI: 1.17–5.20) and 2.34 (95% CI: 1.33–4.13)-fold risk for
breast cancer and 2.70-(95% CI: 1.23–5.90) and 2.31 (95% CI:
1.27–4.22)-fold risk for ER-positive breast cancer, respectively. A
trend towards higher risk of ER-negative breast cancer with high
levels of ER-b serum bioactivity was observed (OR 2.27 (95% CI:
1.00–5.15)) (Table 3A and B).
In order to test whether the ER-a and ER-b serum bioactivity are
independently associated with breast cancer, a logistic regression
analysis was performed adjusting for the bioactivity of the other
receptor, and for age. Both ER-a and ER-b serum bioactivity were
independently associated with general and ER-positive breast
cancer. Oestrogen receptor-b serum bioactivity, after adjustment
for ER-a serum bioactivity and age, was significantly associated
with general (P¼0.008) and with ER-positive (P¼0.01) breast
cancer. A borderline significant association (P¼0.07) between
ER-b serum bioactivity and ER-negative breast cancer emerged
after adjustment for ER-a serum bioactivity (Table 4).
To test whether a combined approach would increase the
predictive power, the groups defined by first–fourth and fifth
quintile were analysed. Women whose ER-a and ER-b serum
bioactivity were in the fifth quintile of controls had a 7.57-(95% CI:
2.46–23.32) and a 10.14 (95% CI: 3.19–32.23)-fold risk for general
and ER-positive breast cancer, respectively. Women with first–
fourth quintile ER-a serum bioactivity and fifth quintile ER-b
Table 2 Correlation coefficients (Spearman) between oestrogen receptor a (ER-a), ER-b serum bioactivity and serum oestradiol
Sample
ER-a and ER-b serum
bioactivity
ER-a serum bioactivity and
oestradiol
ER-b serum bioactivity and
oestradiol
Total (N¼293) 0.08 0.08 0.00
P¼0.15 P¼0.18 P¼0.98
ER-b serum bioactivity 40( N¼127) 0.18 0.09 0.03
P¼0.05 P¼0.30 P¼0.74
Oestradiol 412 (N¼178) 0.11 0.18  0.05
P¼0.16 P¼0.02 P¼0.52
ER-b serum bioactivity 40 and oestradiol 412
(N¼79)
0.22 0.18 0.10
P¼0.05 P¼0.11 P¼0.40
Table 3A Association of oestrogen receptor a (ER-a) serum bioactivity with risk of breast cancer
Cases
ER-a serum bioactivity (pgml
 1)
Controls
All ER-negative ER-positive
Quintile
a Range N (%) N (%) OR (95% CI)
b N (%) OR (95% CI)
b N (%) OR (95% CI)
b
1st 0–13.8 24 (19.1) 24 (14.3) 1.00 (ref.) 4 (9.5) 1.00 (ref.) 20 (15.9) 1.00 (ref.)
2nd 13.9–21.6 26 (20.8) 25 (14.9) 1.00 (0.45–2.23) 7 (16.7) 1.53 (0.39–6.06) 18 (14.3) 0.92 (0.39–2.18)
3rd 21.7–29.5 25 (20.0) 23 (13.7) 0.97 (0.43–2.17) 12 (28.6) 3.22 (0.88–11.77) 11 (8.7) 0.53 (0.21–1.36)
4th 29.6–42.0 25 (20.0) 33 (19.6) 1.24 (0.57–2.71) 10 (23.8) 2.18 (0.59–8.11) 23 (18.3) 1.09 (0.47–2.52)
5th X42.1 25 (20.0) 63 (37.5) 2.47 (1.17–5.20) 9 (21.4) 1.84 (0.49–6.89) 54 (42.9) 2.70 (1.23–5.90)
P-value
c P¼0.008 P¼0.36 P¼0.004
aQuintiles according to distribution among controls.
bAdjusted for age.
cP-value for trend, adjusted for age.
Table 1 Oestrogen receptor a (ER-a) and ER-b serum bioactivity in
serum samples from 125 controls and from168 breast cancer cases
Group
Cases
Characteristic Controls All ER-negative ER-positive
N 125 168 42 126
ER-a serum bioactivity (pgml
 1)
Range 0–111.8 0–298.3 6.7–131.8 0–298.3
Mean 30.5 50.7 33.9 56.3
Median 25.6 33.0 27.9 37.1
P-value
a P¼0.002 P¼0.18 P¼0.001
ER-b serum bioactivity (pgml
 1)
Range 0–315.7 0–844.6 0–583.7 0–844.6
Mean 37.4 93.5 77.9 98.7
Median 0.0 0.0 0.0 0.0
P-value
a P¼0.004 P¼0.08 P¼0.005
aKruskal–Wallis test for difference in mean value among case group and controls.
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sserum bioactivity had a 2.36-(0.97–5.69) fold risk for ER-negative
breast cancer (Table 5). The observed patterns were independent
of the defined cutoff, although the strength of associations
increased with the increasing cut-points: Women whose ER-a
and ER-b serum bioactivity were in the top tertile, quartile or 490
percentile had a 4.47-(95% CI: 2.06–9.70; P¼0.0002), 5.52-(95%
CI: 2.34–13.01; Po0.0001) or 12.76 (95% CI: 1.60–101.97;
P¼0.16)-fold risk for general and a 5.30-(95% CI: 2.34–11.99;
Po0.0001), 7.16-(95% CI: 2.92–17.57; Po0.0001) or 19.47 (95%
CI: 2.38–159.03; Po0.0001)-fold risk for ER-positive breast
cancer, respectively, compared with women with ER-a and ER-b
serum bioactivity below the respective cutoff points.
DISCUSSION
In this paper, we describe for the first time a yeast-based serum
bioactivity assay to predict the presence of breast cancer. To date,
there have been no reports showing such a significant association
between the high serum hormone levels and the presence of any
endocrine-related cancer.
In postmenopausal women, both ER-a and ER-b serum bioactivity
were significantly different between patients with breast cancer and
age-matched controls, whereas there was no difference in serum
oestradiol levels between the two groups. The oestradiol findings are
in keeping with a recent retrospective analysis of data from
Table 3B Association of oestrogen receptor b (ER-b) serum bioactivity with risk of breast cancer
Cases
ER-b serum bioactivity (pgml
 1)
Controls
All ER-negative ER-positive
Quintile
a Range N (%) N (%) OR (95% CI)
b N (%) OR (95% CI)
b N (%) OR (95% CI)
b
1st–3rd 0 80 (64.0) 86 (51.2) 1.00 (ref.) 22 (52.4) 1.00 (ref.) 64 (50.8) 1.00 (ref.)
4th 0.1–53 20 (16.0) 21 (12.5) 0.97 (0.48–1.96) 4 (9.5) 0.77 (0.23–2.57) 17 (13.5) 1.03 (0.49–2.17)
5th 453 25 (20.0) 61 (36.3) 2.34 (1.33–4.13) 16 (38.1) 2.27 (1.00–5.15) 45 (35.7) 2.31 (1.27–4.22)
P-value
c P¼0.005 P¼0.07 P¼0.009
aQuintiles according to distribution among controls.
bAdjusted for age.
cP-value for trend, adjusted for age.
Table 4 Association of oestrogen receptor a (ER-a) and ER-b serum bioactivity (controlled for each other) with risk of breast cancer; classification
according to quintiles among controls
Cases
Controls
All ER-negative ER-positive
Quintile
a Range (pgml
 1) N (%) N (%) OR (95% CI)
b N (%) OR (95% CI)
b N (%) OR (95% CI)
b
ER-a serum bioactivity
1st 0–13.8 24 (19.2) 24 (14.3) 1.00 (ref.) 4 (9.5) 1.00 (ref.) 20 (15.9) 1.00 (ref.)
2nd 13.9–21.6 26 (20.8) 25 (14.9) 0.99 (0.44–2.27) 7 (16.7) 1.52 (0.38–6.16) 18 (14.3) 0.91 (0.38–2.22)
3rd 21.7–29.5 25 (20.0) 23 (13.7) 0.82 (0.35–1.91) 12 (28.6) 2.80 (0.73–10.67) 11 (8.7) 0.44 (0.17–1.18)
4th 29.6–42.0 25 (20.0) 33 (19.6) 1.07 (0.47–2.43) 10 (23.8) 2.02 (0.53–7.78) 23 (18.3) 0.94 (0.39–2.28)
5th X42.1 25 (20.0) 63 (37.5) 2.24 (1.04–4.81) 9 (21.4) 1.80 (0.47–6.90) 54 (42.9) 2.43 (1.09–5.44)
P-value
c P¼0.01 P¼0.34 P¼0.007
ER-b serum bioactivity
1st–3rd 0 80 (64.0) 86 (51.2) 1.00 (ref.) 22 (52.4) 1.00 (ref.) 64 (50.8) 1.00 (ref.)
4th 0.1–53 20 (16.0) 21 (12.5) 0.94 (0.45–1.96) 4 (9.5) 0.92 (0.27–3.14) 17 (13.5) 0.93 (0.42–2.06)
5th 453 25 (20.0) 61 (36.3) 2.32 (1.04–4.81) 16 (38.1) 2.12 (0.92–4.87) 45 (35.7) 2.36 (1.26–4.43)
P-value
c P¼0.008 P¼0.07 P¼0.01
aQuintiles according to distribution among controls.
bAdjusted for age and other marker.
cP-value for trend, adjusted for age and other marker.
Table 5 Joint association of high oestrogen receptor a (ER-a) serum bioactivity (5th quintile) and high ER-b serum bioactivity (5th quintile) with risk of
breast cancer
Quintilea
Cases
Range
Controls
All ER-negative ER-positive
ER-a serum bioactivity ER-b serum bioactivity N (%) N (%) OR (95% CI)
b N (%) OR (95% CI)
b N (%) OR (95% CI)
b
1st–4th 1st–4th 79 (63.2%) 69 (41.1%) 1.00 (ref.) 20 (47.6%) 1.00 (ref.) 49 (38.9%) 1.00 (ref.)
0–42pgml
 1 0–53pgml
 1
5th 1st–4th 21 (16.8%) 38 (22.6%) 1.97 (1.05–3.72) 6 (14.3%) 0.99 (0.35–2.81) 32 (25.4%) 2.41 (1.23–4.72)
442pgml
 1 0–53pgml
 1 P¼0.04 P¼0.98 P¼0.01
1st–4th 5th 21 (16.8%) 36 (21.4%) 1.98 (1.05–3.75) 13 (31.0%) 2.36 (0.97–5.69) 23 (18.3%) 1.77 (0.88–3.58)
0–42pgml
 1 453pgml
 1 P¼0.03 P¼0.06 P¼0.11
5th 5th 4 (3.2%) 25 (14.9%) 7.57 (2.46–23.32) 3 (7.1%) 2.36 (0.47–11.79) 22 (17.5%) 10.14 (3.19–32.23)
442pgml
 1 453pgml
 1 P¼0.0004 P¼0.30 Po0.0001
P-value for trend
c Po0.0001 P¼0.14 Po0.0001
aQuintiles according to distribution among controls.
bAdjusted for age.
cIn an analysis combining categories 2 and 3, adjusted for age.
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sprospective studies, in which neither total (relative risk 1.21, 95% CI:
0.99–1.47) nor free serum oestradiol (relative risk 1.18, 95% CI:
0.98–1.43) was an increased risk marker for women who were
diagnosed with breast cancer shortly after the blood collection
(Key et al, 2002). Our results show that the serum bioactivity assay,
which estimates the total functional oestrogenic activity, is better
than conventional hormonal assays for estimating breast cancer risk.
The assay is able to quantify the effect of all circulating active
oestrogen metabolites, as well as other substances that can activate
the oestrogen receptors and induce gene transcription.
In the retrospective analysis referred to above, analysis of the
majority of hormones in postmenopausal women shows a some-
what greater cancer risk in patients who were diagnosed 2 or more
years after blood collection than in patients who were diagnosed
within 2 years of blood collection (Key et al, 2002). This suggests
that these functional assays may have more predictive power when
analysing samples preceding diagnosis and, as a consequence,
could provide an excellent means of screening for breast cancer. A
study, supportive of this view, is currently underway using samples
from women who developed cancer in the UK Collaborative Trial
of Ovarian Cancer Screening.
In ER-positive breast cancer, the combination of high-ER-a and
high-ER-b serum bioactivity were associated with a 10.14-fold risk
of breast cancer. This is far higher than the 2–2.5-fold risk
reported with elevated serum oestrogenic activity measured using
hormonal assays in similar case–control studies. The bioactivity
assay, unlike conventional hormonal measurements, is able to act
as a surrogate biomarker for the potential of all factors in the
serum to transactivate the two different ERs, namely ER-a and ER-
b. Activation of ER-a by means of oestradiol and inhibition of ER-
a by means of tamoxifen, or indirectly by means of aromatase
inhibitors, increases and decreases ER-positive breast cancer risk,
respectively (Cuzick et al, 2003; Yager and Davidson, 2006).This is
consistent with our finding that ER-a serum bioactivity predicts
ER-positive, but not ER-negative breast cancer.
Entirely unexpectedly, high levels of ER-b serum bioactivity,
after adjustment for ER-a serum bioactivity and age, were found to
be associated with increased risk for ER-positive and ER-negative
breast cancer. Although it is generally assumed that the growth of
ER-negative breast cancers is not influenced by oestrogens, there is
an evidence to suggest that oophorectomy prevents the formation
of both ER-positive and ER-negative breast cancers (Nissen-Meyer,
1964; Early Breast Cancer Trialists’ Collaborative Group, 1992),
indicating that even ER-negative breast cancers may depend on
hormones for their formation. BRCA1-associated tumours,
the vast majority of which are ER-negative, are also effectively
prevented by removal of the ovaries (Rebbeck et al, 2002).
Recent evidence suggested that oestrogens facilitate ER-negative
breast carcinogenesis by modulating stromal components
(Gupta et al, 2007). The main component of breast stroma,
namely mammary fibroblasts, only expresses ER-b but lack
expression of ER-a (Palmieri et al, 2004). A simple explanation
for our finding could be that compounds in the serum-activating
ER-b (as reflected by high-ER-b serum bioactivity) facilitate ER-
negative breast carcinogenesis by activating breast fibroblasts.
Interestingly, there was only a weak correlation between
oestradiol and ER-a serum bioactivity and only in women with
oestradiol levels higher than the threshold for functional sensitivity
(412pgml
 1). In addition, we could not find a correlation
between oestradiol and ER-b serum bioactivity, although oestra-
diol is known to bind to both receptors. ER-a and ER-b serum
bioactivity, independent of each other predicts the presence of
breast cancer. Compared with the ‘best ligand’ oestradiol, the
corresponding ER-a and ER-b serum bioactivity are at least 2–3
times higher (data not shown). This can be explained by the
presence of a variety of additional oestrogenic compounds in the
serum, which transactivate both ER proteins in different ways (i.e.,
17-a-oestradiol, phytoestrogens and so on) (Sievernich et al, 2004;
Hasenbrink et al, 2006). In addition, non-steroidal factors in the
serum, which have an impact on the capacity to transactivate ER-a
or ER-b, may also contribute to the higher ER-a and ER-b
bioactivity compared with oestradiol levels in serum. It is known that
steroid-independent pathways exist for activation of a steroid
receptor through signalling cascades from membrane-regulatory
molecules, such as cAMP, dopamine, growth factors, cytokines, and
possibly other cellular regulators acting at the membrane (Aronica
and Katzenellenbogen, 1993; Ignar-Trowbridge et al, 1993; O’Malley,
2005). Therefore, we speculate that the serum contains steroid-
independent co-activators, which have an impact on breast
carcinogenesis and are reflected by ER-a and ER-b serum bioactivity.
Two types of immunoassay can be used to measure total
oestradiol: indirect assays use a pre-analytical extraction step with
organic solvent to dissociate oestradiol from its binding proteins
and remove potentially cross-reacting hydrophilic steroid con-
jugates, whereas direct assays employ an agent with greater affinity
for the binding of proteins that then displace oestradiol. Indirect
assays are typically more sensitive and accurate. Here, we used a
direct automated immunoassay. This may be an additional
explanation for the lack of correlation between oestradiol and
ER-a or ER-b serum bioactivity.
In summary, serum bioactivity assays for both ER-a and ER-b
predict ER-positive breast cancer at the time of diagnosis. In
addition, the serum bioactivity of ER-b controlled for the activity of
ER-a is tentatively associated with ER-negative breast cancer. The
findings of this proof of principle study may have the potential to
open up an entirely new window of opportunity to: (a) predict breast
cancer and (b) allow monitoring of preventive and therapeutic
hormonal therapies (tamoxifen or aromatase inhibitors) in breast
cancer. These issues need to be addressed in future studies.
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